Kazia Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
John Friend
Chief executive officer
AU$1.6m
Total compensation
| CEO salary percentage | 47.1% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Jun 24
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Feb 24We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned
Nov 03We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
Sep 23We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
May 04When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
Mar 27Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Feb 28What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?
Feb 01
We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
Jan 06Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts
Dec 11Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | AU$2m | AU$743k | -AU$20m |
| Mar 31 2023 | n/a | n/a | -AU$23m |
| Dec 31 2022 | n/a | n/a | -AU$25m |
| Sep 30 2022 | n/a | n/a | -AU$25m |
| Jun 30 2022 | AU$1m | AU$430k | -AU$25m |
Compensation vs Market: John's total compensation ($USD1.03M) is above average for companies of similar size in the Australian market ($USD295.83K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Friend (53 yo)
less than a year
Tenure
AU$1,576,913
Compensation
Dr. John E. Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Medic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Interim Chairman | less than a year | AU$1.58m | no data | |
| Chief Financial Officer | 1.8yrs | AU$1.05m | no data | |
| Company Secretary | less than a year | no data | no data |
0.8yrs
Average Tenure
Experienced Management: KZA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Interim Chairman | less than a year | AU$1.58m | no data | |
| Independent Non-Executive Director | 8.4yrs | AU$94.00k | 0.36% A$ 68.5k | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | 11yrs | AU$94.00k | 0.42% A$ 79.4k | |
| Director | less than a year | AU$7.12k | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data |
1.3yrs
Average Tenure
61yo
Average Age
Experienced Board: KZA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.